AI Drug R&D Startup XtalPi Lands Massive $319M SoftBank-Led Round C To Continue Its High-Tech Drug Discovery
| < 1 minute read
XtalPi, an American-Chinese biotech firm that focuses on AI-assisted drug discovery, has raised a $319 million round C from a slate of enthusiastic investors led by SoftBank’s Vision Fund. It joins numerous others with 9-figure rounds in what is clearly a valuable and competitive space.
XtalPi works with major pharmaceutical companies like Pfizer that need to identify promising new drug-like molecules and learn as much about them as possible.
XtalPi will expand its Intelligent Digital Drug Discovery and Development (ID4) platform’s capabilities through a three-pronged approach focused on algorithms, data, and computing power to address efficiency bottlenecks throughout the critical steps of pharmaceutical research.
Across several prominent global cloud providers, XtalPi routinely builds a supercomputing cluster of over a million cores on-the-fly, in just a few hours, to enable dozens of drug discovery and design projects in parallel. In developing its digital-twin drug R&D system, XtalPi will continue to match real-world R&D data with increasingly powerful virtual simulations at scale and extend its existing success to serve a larger number of biotech partners, therapeutic areas, and drug discovery projects.